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Anti-thymocyte globulin for graft-versus-host disease prophy-
laxis in patients with intermediate- or high-risk acute myeloid
leukaemia undergoing reduced-intensity conditioning allo-
geneic stem cell transplantation in first complete remission – a
survey on behalf of the Acute Leukaemia Working Party of the
European Society for Blood and Marrow Transplantation
Rabbit anti-thymocyte globulins (ATG) are commonly used
for prophylaxis of graft-versus-host disease (GVHD) when
prescribed as part of conditioning therapy for allogeneic stem
cell transplantation (Allo-SCT). A review emphasizing the
beneficial ATG effect on GVHD incidence was recently pub-
lished (Baron et al, 2017). Surprisingly, retrospective trials
describing a dramatic chronic GVHD (cGVHD) rate reduc-
tion (Socie et al, 2011; Baron et al, 2014) and prospective,
randomized trials confirming ATG anti-GVHD activity
(Finke et al, 2009; Kroger et al, 2016; Walker et al, 2016;
Soiffer et al, 2017) as well as a trial using a pre-emptive regi-
men (Bacigalupo et al, 2010) failed to demonstrate a statisti-
cally significant survival benefit of ATG use. Although the
use of reduced-intensity conditioning (RIC) is growing, these
patients are underrepresented in prospective ATG trials.
The current retrospective multicentre analysis, designed
by the European Society for Blood and Marrow Transplanta-
tion (EBMT) Acute Leukaemia (AML) Working Party,
aimed to explore the role of high and intermediate doses of
ATG administered as part of RIC in adult high-risk AML
patients transplanted while in first complete remission
(CR1). The study was approved by institutional review
boards of all the EBMT-affiliated centres and was conducted
in accordance with the Declaration of Helsinki and Good
Clinical Practice guidelines, relying on patients’ informed
consent authorizing the use of their personal information
for research purposes. All of the participating centres are
listed in Appendix S1.
The analysis included: adult AML patients
(aged ≥ 18 years) with high-risk features (intermediate/poor-
risk cytogenetics or secondary AML) who underwent a first
RIC Allo-SCT (Baron et al, 2016) from either matched
related or unrelated donors, while in CR1, between the years
2000 and 2014. Grafts could originate from peripheral blood
or bone marrow of donors with 10/10 or 9/10 locus match-
ing.
High-dose ATG was defined as >15 mg/kg of any brand or
>6 mg/kg of ATG-thymoglobulin (ATG-T). The following
doses were considered intermediate: 3–6 mg/kg of ATG-T,
75–15 mg/kg of ATG-Fresenius (ATLG) or <15 mg/kg of an
unspecified brand. All other patients formed the control group.
Exclusion criteria were: previous Allo-SCT, any kind of
ex vivo T cell depletion or alemtuzumab use. Patients with
favourable cytogenetics were also excluded.
The primary endpoint of the study was GVHD-free
relapse-free survival (GRFS) (Ruggeri et al, 2016). Secondary
endpoints were: leukaemia-free survival (LFS), cGVHD,
extensive cGVHD, relapse incidence (RI), non-relapse mor-
tality (NRM) and OS.
Grading of acute and cGVHD was performed using estab-
lished criteria. cGVHD was classified as limited or extensive
according to standard criteria. Cumulative incidence of relapse
and NRM were analysed as competing parameters. OS and
LFS probabilities were calculated using the Kaplan–Meier esti-
mate. All tests were two-sided with the type I error rate fixed
at 005. Statistical analyses were performed with SPSS 19 (SPSS
Inc., Chicago, IL, USA), and R 3.0.1 (R Development Core
Team, Vienna, Austria) software packages.
Data on 1750 AML patients were included in this analysis
(205 received high ATG doses, 358 – intermediate doses, and
1187 – no ATG). Groups were comparable in terms of
patient and donor characteristics (Table I), although the pro-
portion of patients with secondary AML was greater in the
high-dose group. Following ATG prophylaxis, cGVHD rates
at 1 and 3 years post-transplant were reduced by up to 50%,
irrespective of the dose used (after 1 year: from 429% to
278% [246%]; after 3 years: from 487% to 316% [258%];
P < 00001). The corresponding values for extensive cGVHD
were 229%, 139% and 109% after 1 year and 286%,
164% and 136% after 3 years (Table II). This reduction in
cGVHD rate was reflected in GRFS improvement at both 1
and 3 years of follow-up (from 413% to 48% [497%] and
from 293% to 373% [36%], respectively; P = 00069). The
addition of ATG to conditioning regimens did not affect
NRM, OS or LFS (Table II). Notably, ATG was associated
with a rise in RI both at 1 and 3 years post-transplant,
although this difference did not reach statistical significance
(Table II).
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In multivariate analysis, only patient age, cytogenetics and
donor cytomegalovirus status significantly affected OS and
LFS. ATG administration was identified as a significant factor
influencing cGVHD, RI, NRM and GRFS, regardless of the
prescribed dose. Female-to-male transplant was associated
with higher cGVHD rates and decreased GRFS. ATG use was
related to reduction in the extensive cGVHD rate, with a
hazard ratio of 054 for intermediate and 04 for high dose
(P < 0001).
Although the specific ATG brand used was not recorded
for many patients, it could be assumed that all patients in
the low-dose group received ATG-T, whereas patients
receiving doses >40 mg/kg could be considered as treated
with ATLG. While the latter group included only 41
patients, it is worth mentioning due to very low cGVHD
and extensive cGVHD rates (218% and 55%) at both 1
and 3 years. This achievement was associated with GRFS
increase to 567% and 423% for 1 and 3 years, without
OS benefit.
Our analysis has shown that in the RIC context, ATG
administration is associated with decreased GVHD inci-
dence and severity. It is intriguing that the therapy which
Table I. Patient characteristics.
Variable
No ATG or dose <3 or
75 mg/kg (n = 1187)
ATG dose 3–6 or
75–15 mg/kg (n = 358)
ATG and dose >6 or
15 mg/kg (n = 205) All patients (n = 1750) P value
Follow-up for survivors, months
Median (range) 527 (00–1773) 271 (00–1591) 429 (07–1566) 446 (0–1773) <00001
Age at transplant, years
Median (range) 570 (181–758) 580 (271–703) 566 (205–704) 573 (181–758) 0054
Time from diagnosis to transplant, days
Median (range) 1460 (90–4510) 1660 (430–4340) 153 (43–11 248) 153 (9–11 338) <00001
Year of transplant
Median (range) 2008 (2000–2014) 2011 (2000–2014) 2009 (2000–2014) 2009 (2000–2014) <00001
Patient gender, n (%)
Male 636 (536) 199 (556) 107 (522) 942 (538) 071
Female 551 (464) 159 (444) 98 (478) 808 (462)
Donor gender, n (%)
Male 606 (514) 202 (564) 112 (546) 920 (528) 022
Female 572 (486) 156 (436) 93 (454) 821 (472)
Sex mismatch, n (%)
Female to male 297 (252) 81 (226) 48 (234) 426 (245) 057
Other combinations 881 (748) 277 (774) 157 (766) 1315 (755)
Donor CMV, n (%)
Negative 402 (350) 158 (443) 85 (425) 645 (378) 0002
Positive 746 (650) 199 (557) 115 (575) 1060 (622)
Patient CMV, n (%)
Negative 323 (281) 136 (382) 65 (319) 524 (306) 0001
Positive 828 (719) 220 (618) 139 (681) 1187 (694)
CMV match patient/donor, n (%)
/ 197 (173) 95 (268) 43 (216) 335 (198) 0003
/+ 121 (106) 41 (115) 21 (106) 183 (108)
+/ 201 (177) 62 (175) 41 (206) 304 (18)
+/+ 619 (544) 157 (442) 94 (472) 870 (514)
Stem cell source, n (%)
BM 136 (78) 111 (94) 11 (54) 136 (78) 0009
PB 1606 (918) 1070 (901) 193 (941) 1606 (918)
BM+PB 8 (05) 6 (05) 1 (05) 8 (05)
Cytogenetics, n (%)
Intermediate 673 (567) 200 (559) 93 (454) 966 (552) 0002
Poor 185 (156) 62 (173) 28 (137) 275 (157)
Secondary AML, n (%) 329 (277) 96 (268) 84 (41) 509 (291)
Use of TBI, n (%)
No 697 (587) 350 (978) 167 (815) 1214 (694)
Yes 490 (413) 8 (22) 38 (185) 536 (306)
AML, acute myeloid leukaemia; ATG, antithymocyte globulin; BM, bone marrow; CMV, cytomegalovirus; PB, peripheral blood; TBI, total body
irradiation.
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spares a marked proportion of patients from devastating
extensive cGVHD is not associated with OS improvement.
Indeed, due to the noteworthy reduction in extensive
GVHD rate, despite an increase in relapse rate and NRM,
the composite GRFS endpoint was improved by 7–8%.
Most important is our finding that intermediate and high
doses of ATG have similar effects. This result emphasizes
the need for comparisons of patients receiving different
ATG doses and the use of a homogenous control group
receiving no ATG at all.
Our findings should be cautiously interpreted due to limi-
tations of registry-derived data that may be affected by
patient selection biases and missing data. We were unable to
analyse the effect of different brands of ATG separately.
However, the very good outcome of patients receiving doses
>40 mg, assumed to be ATLG, warrants further studies of
this regimen.
In the current study, ATG incorporation in RIC regi-
mens significantly improved GRFS, which is definitely a
desirable outcome from patient’s perspective. Overall, ATG
is a powerful tool for GVHD prophylaxis. Further stud-
ies are required to determine whether the use of a speci-
fic ATG dose or brand could improve the clinical
outcome.
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